Bristol-Myers Squibb Company (BMY)

BMY (NYSE:Drugs)
neg -0.11
Today's Range: 50.44 - 50.97 | BMY Avg Daily Volume: 8,531,600
Last Update: 08/01/14 - 10:31 AM EDT
Volume: 932,548
YTD Performance: -4.76%
Open: $50.79
Previous Close: $50.62
52 Week Range: $41.11 - $57.49
Oustanding Shares: 1,657,904,666
Market Cap: 84,752,086,526
6-Month Chart
TheStreet Ratings Grade for BMY
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 8 9 9 10
Moderate Buy 1 1 1 1
Hold 7 6 5 5
Moderate Sell 0 0 0 0
Strong Sell 1 1 2 2
Mean Rec. 2.09 1.97 2.09 2.03
Latest Dividend: 0.36
Latest Dividend Yield: 2.82%
Dividend Ex-Date: 07/01/14
Price Earnings Ratio: 31.75
Price Earnings Comparisons:
BMY Sector Avg. S&P 500
31.75 31.70 28.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
1.06% 17.07% 76.62%
Revenue -7.00 -0.16 -0.06
Net Income 3.20 -0.43 -0.17
EPS 32.90 -0.13 -0.05
Earnings for BMY:
Revenue 16.39B
Average Earnings Estimates
Qtr (09/14) Qtr (12/14) FY (12/14) FY (12/15)
Average Estimate $0.42 $0.43 $1.78 $1.69
Number of Analysts 8 7 12 11
High Estimate $0.48 $0.46 $1.81 $1.96
Low Estimate $0.36 $0.39 $1.71 $1.40
Prior Year $0.46 $0.51 $1.82 $1.78
Growth Rate (Year over Year) -8.15% -16.25% -2.47% -4.64%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
We have seen a huge correction, and we now need to look for signs that it is ending.
Weak competitors are now serving as prime takeover targets.
A wave of M&A in the health sector makes sense.
Standing still is no longer an option.

Contradictory Market Messages Real Money Pro($)

The continued indecision actually narrows your options.
Jun 24, 2014 | 7:43 AM EDT
BMY lowered its number, Jefferies said. Reflecting lowered estimates on nivo and ipi and increasing pressure on operational margin. $42...

Two Shorts and a Long Real Money Pro($)

LinkedIn is looking like a nice buy, while Bristol-Myers and Amazon would become shorts at these levels.
Jun 11, 2014 | 8:28 AM EDT
BMY lowered its number, Jefferies said. M&A activity and ASCO has been disruptive. $47 price target and Hold rating. 
Jun 10, 2014 | 7:42 AM EDT
Goldman Sachs Healthcare Conference (Day 1 of 3) - 06/10/14 - 06/12/14 Los Angeles, CA
Become more aggressive about the real valuations of companies.

Columnist Conversations

This weeks Pick of the Week from me is Herbalife (HLF) for a quick dead-cat-bounce play after the last earning...
Jacobs Engineering (JEC) touched a new 52-week low making the shares a tempting buy today. It also looks good ...
I suspect many Fed members and economists still believe in the Philips Curve Model in that wages rise and fall...
Grading the company on a curve, WU reported surprisingly okay quarterly results (recent quarters and outlooks ...


Columnist Tweets


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.